Clostridium butyricum is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Second Affiliated Hospital, Zhejiang University, School of Medicine (1). The most-studied condition is Colon Neoplasm.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia
NCT07182890 · ClinicalTrials.gov ↗ · Functional Dyspepsia, Probiotics, Depression
|
Phase 4 | Recruiting | Xijing Hospital of Digestive Diseases | China |
|
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
NCT05914389 · ClinicalTrials.gov ↗ · Colon Neoplasm
|
Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
NCT06696742 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer
|
Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | China |
|
The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer
NCT07152886 · ClinicalTrials.gov ↗ · Colorectal Cancer, Chemotherapeutic Toxicity
|
Phase 4 | Not yet open | The Affiliated Hospital of Qingdao University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Xijing Hospital of Digestive Diseases | 1 |
| The Affiliated Hospital of Qingdao University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Clostridium butyricum as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Second Affiliated Hospital, Zhejiang University, School of Medicine (1), The First Affiliated Hospital with Nanjing Medical University (1), Xijing Hospital of Digestive Diseases (1) and The Affiliated Hospital of Qingdao University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Clostridium butyricum works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Clostridium butyricum works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Clostridium butyricum (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.